MedTrace Logo

Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

NCT00358202 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2007-10-31

No results posted yet for this study

Summary

Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.

Conditions

Interventions

DRUG

cefepime

cefepime hydrochloride 1gm IM q24h

DRUG

ceftriaxone

ceftriaxone 1 gm IM q24h

Sponsors & Collaborators

  • Elan Pharmaceuticals

    collaborator INDUSTRY

  • CPL Associates

    lead OTHER

Principal Investigators

  • Joseph A Paladino, PharmD · CPL Associates, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Completion
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358202 on ClinicalTrials.gov